APA

Fuster D., Huertas J. A., Gómez G., Solà R., González García J., Vilaró J., Pedrol E., Force L., Tor J., Sirera G., Videla S., Planas R., Clotet B. & Tural C. (20060821). Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. : Antiviral therapy.

Chicago

Fuster Daniel, Huertas Jaime A, Gómez Guadalupe, Solà Ricard, González García Juan, Vilaró Josep, Pedrol Enric, Force Lluís, Tor Jordi, Sirera Guillem, Videla Sebastiá, Planas Ramon, Clotet Bonaventura and Tural Cristina. 20060821. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. : Antiviral therapy.

Harvard

Fuster D., Huertas J. A., Gómez G., Solà R., González García J., Vilaró J., Pedrol E., Force L., Tor J., Sirera G., Videla S., Planas R., Clotet B. and Tural C. (20060821). Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. : Antiviral therapy.

MLA

Fuster Daniel, Huertas Jaime A, Gómez Guadalupe, Solà Ricard, González García Juan, Vilaró Josep, Pedrol Enric, Force Lluís, Tor Jordi, Sirera Guillem, Videla Sebastiá, Planas Ramon, Clotet Bonaventura and Tural Cristina. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. : Antiviral therapy. 20060821.